Establishes "New Jersey Right to Try for Individualized Treatments Act."

2026-2027 Regular Session Introduced by Paul Kanitra

Establishes a pathway for eligible patients to access experimental or individualized treatments not yet FDA-approved, with oversight and patient protections.

Summary of A 5231 (New Jersey, 222nd Session)

Purpose and intent

Establishes the “New Jersey Right to Try for Individualized Treatments Act.”

Aims to provide a pathway for certain patients with life-threatening or seriously debilitating conditions to access experimental or individualized treatments that have not yet been approved by standard regulatory processes.

Key provisions and changes

Eligibility and access

May create a statutory framework permitting eligible patients to seek access to individualized or experimental treatments outside of conventional clinical trial or fully FDA-approved pathways.
Likely defines criteria for patient eligibility (e.g., diagnosis, lack of alternative approved therapies, and determination of potential benefit) and requires reasonable efforts to pursue available options.

Treatment requests and processes

Establishes an process for patients, physicians, and treatment providers to request access to experimental therapies.
May require medical justification, documentation of risk/benefit, and an assessment of patient informed consent.
Could specify timelines for agency or sponsor responses and approval decisions to avoid undue delays.

Providers and facilities

Addresses roles and responsibilities of physicians, medical facilities, and sponsors of investigational products in offering or administering qualifying treatments.
May include requirements for adverse event reporting and monitoring of treatment outcomes.

Protections and limitations

Likely includes patient protections around cost responsibility, patient privacy, and informed consent.
May define limitations related to liability, physician duties, and risk disclosure to align with patient autonomy while safeguarding against unsafe practices.

Regulatory or oversight elements

Could outline oversight mechanisms, such as a governing body or health department review, to ensure treatments meet defined standards for access.
May set reporting or annual review requirements to monitor utilization and outcomes.

Who would be affected

Patients with life-threatening or seriously debilitating conditions seeking access to experimental or individualized treatments not yet approved in the standard regulatory framework.

Physicians and healthcare providers offering such treatments.

Treatment sponsors or manufacturers of investigational products.

Healthcare facilities participating in the program.

State health department or relevant regulatory agency implementing and overseeing the program.

Procedural and timeline aspects

Likely establishes a formal application or request timeline for access decisions.

May require informed consent procedures and documentation within specified timeframes.

Could set periodic reporting deadlines to track utilization, safety, and outcomes.

Potential impact and considerations

Expands patient access to experimental options, potentially offering treatment avenues when standard therapies are unavailable.

Balances patient autonomy and hope with safety considerations through defined eligibility criteria, oversight, and monitoring.

Could influence costs borne by patients or providers, depending on statutory provisions regarding coverage, reimbursement, and liability.

The specifics of eligibility criteria, oversight structure, and liability protections will significantly shape practical implementation.

Note: This summary is based on the bill’s title and sponsor information. For precise language, definitions, and operative details (including any amendments), reviewing the full text and fiscal notes of A 5231 is recommended.